Enliven Therapeutics (ELVN) Assets Average (2020 - 2026)

Enliven Therapeutics (ELVN) has 7 years of Assets Average data on file, last reported at $470.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 49.77% year-over-year to $470.5 million; the trailing twelve-month figure through Mar 2026 stood at $470.5 million (up 49.77% YoY), and the FY2025 full-year result was $401.0 million, up 34.19% from the prior year.
• Assets Average slipped to $470.5 million in Q1 2026, from $483.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $497.4 million in Q3 2025 to a low of $61.9 million in Q3 2022.
• A 5-year average of $281.2 million and a median of $307.3 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 31.05% in 2022 and jumped 354.51% in 2023, its largest moves.
• Tracing ELVN's Assets Average over 5 years: stood at $71.2 million in 2022, then soared by 283.36% to $273.0 million in 2023, then climbed by 15.62% to $315.6 million in 2024, then surged by 53.21% to $483.5 million in 2025, then retreated by 2.69% to $470.5 million in 2026.
• Business Quant data shows ELVN's Assets Average at $470.5 million in Q1 2026, $483.5 million in Q4 2025, and $497.4 million in Q3 2025.